Office of Nursing Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Breast and Imaging Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Adv Nurs. 2021 Mar;77(3):1556-1566. doi: 10.1111/jan.14659. Epub 2020 Nov 27.
This study will test the feasibility and effectiveness of mobile technology intervention on the patients' self-management of oral anticancer medication. Secondary objectives include acceptability, the usefulness of text messages, and satisfaction by participants and nurses.
This prospective two-arm study will recruit patients (N = 220) with metastatic breast cancer and initiating treatment with palbociclib (Ibrance ®). Allowing for attrition, patients will be randomized into the control (N = 100) or intervention (N = 100) group. Unidirectional text message reminders will be sent during the treatment cycle through a secure web application using the patient's smartphone. Self-reported survey responses will be collected at three time points; at consent, end of treatment cycles, and the follow-up clinic visit and include a demographic questionnaire, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Post study questionnaire and the R-15 Patient Satisfaction Questionnaire. Nurses providing care for study patients will complete the Adaptation of Stamps Nurse Workload questionnaire. Data will be analysed an intent-to-treat analysis comparing the two arms. Study approval was obtained in December 2019 and funded in January 2020.
Smartphones are globally available and have text messaging capability which is increasingly being used as an intervention in healthcare studies. This study will test a low-cost, nurse-led intervention that enhances the patient's experience with oral anti-cancer medications, improves access to care, reduces costs, and improves the satisfaction of nurses caring for oncology patients.
Despite the ease of administering oral anti-cancer medications, oncology patients maynot take them as prescribed and consequently, these factors affect patient outcomes and disease control. Given the importance of taking oral anti-cancer medications and the difficulties patients experience in achieving it, the effective use of mobile technology interventions can actively engage patients in their care and improve medication self-management of anticancer treatment regimens.
本研究旨在测试移动技术干预对口服抗癌药物患者自我管理的可行性和有效性。次要目标包括可接受性、短信的有用性以及参与者和护士的满意度。
这是一项前瞻性的双臂研究,将招募接受哌柏西利(Ibrance®)治疗的转移性乳腺癌初治患者(N=220)。考虑到患者流失,将患者随机分为对照组(N=100)或干预组(N=100)。通过使用患者智能手机的安全网络应用程序,单向发送治疗周期期间的短信提醒。自我报告的调查结果将在三个时间点收集;在同意时、治疗周期结束时和随访诊所就诊时,包括人口统计学问卷、欧洲癌症研究和治疗组织生活质量问卷、研究后问卷和 R-15 患者满意度问卷。提供研究患者护理的护士将完成邮票护士工作量问卷的适应性部分。将根据意向治疗分析比较两组数据。该研究于 2019 年 12 月获得批准,并于 2020 年 1 月获得资助。
智能手机在全球范围内可用,并且具有短信功能,越来越多地被用作医疗保健研究中的干预措施。本研究将测试一种低成本、护士主导的干预措施,该措施增强了患者对口服抗癌药物的体验,改善了对护理的获取,降低了成本,并提高了护理肿瘤患者的护士满意度。
尽管口服抗癌药物的管理很容易,但肿瘤患者可能无法按规定服用这些药物,因此这些因素会影响患者的结局和疾病控制。鉴于服用口服抗癌药物的重要性以及患者在实现这一目标时遇到的困难,移动技术干预的有效利用可以积极地让患者参与到他们的护理中,并改善抗癌治疗方案的药物自我管理。